worldwide

  1. P

    CytRx Phase II Trial for ALS - arimoclomol

    CytRx Phase II Trial for ALS (Lou Gehrig's Disease) Expected to Begin After Second Quarter Monday June 20, 8:30 am ET Company responds to FDA request for information regarding arimoclomol CytRx Corporation (Nasdaq: CYTR - News), a biopharmaceutical company engaged in the development and...
Back
Top